Tag: Biotechnology
-
Fat cat? Weight-loss drugs may be coming for your overweight pet
Startups are testing GLP-1 treatments for overweight cats while pet-food giants are leaning into longevity products as owners spend more on animal health.
-
UnitedHealth blows past estimates, hikes earnings outlook as it reins in costs
The healthcare giant is working to stabilize margins by shrinking membership, exiting unprofitable contracts and pouring $1.5 billion into AI.
-
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk’s obesity injection Wegovy and diabetes counterpart Ozempic.
-
Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
Its latest fundraising round provides the French biotech with enough cash to finance operations through 2029.
-
Jim Cramer says this former Covid market darling is finally investable again
CNBC’s Jim Cramer said Moderna’s expanding pipeline in treatments for cancer and other diseases provides a compelling long-term investment thesis.
-
Medicare will start covering obesity drugs for the first time. Here’s what patients should know
The move could unlock millions of new patients for Novo Nordisk and Eli Lilly and expand access to medications that were previously out of reach for seniors.
-
Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet
Many seniors may be unaware of the landmark coverage shift starting on July 1, with limited advertising seen from the government or Eli Lilly and Novo.
-
Chan Zuckerberg Initiative’s Biohub to open new rare disease funding round
Chan Zuckerberg Initiative’s Biohub will offer new grants to the rare disease community while expanding its AI drug repurposing partnership with Every Cure.
-
Zealand Pharma stock suffered its two worst days on record. Here’s what’s next for the weight loss drugmaker
While the market’s enthusiasm for one of Zealand’s experimental drugs has cooled, investors are shifting focus to amylin-based medicines as a growth driver
-
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
Latest News
Stay Connected
Categories
BBC News CNA CNBC CNN International Deutsche Welle (DW) Euronews France 24 General Global & European Specialized & Regional
Tags
amp Artificial intelligence Asia Breaking News: Markets Breaking News: Politics Breaking News: Technology Business business news china cup Donald J. Trump Donald Trump economy European Union fast football France germany Heatwave Investment strategy iran Iran war markets news People per politics return russia said Singapore spain Sport Stock markets technology trump ukraine United Kingdom United States US-Israel attack on Iran 2026 video War in Ukraine World world cup World Cup 2026
About the Author
AF themes
Easy WordPress Websites Builder: Versatile Demos for Blogs, News, eCommerce and More – One-Click Import, No Coding! 1000+ Ready-made Templates for Stunning Newspaper, Magazine, Blog, and Publishing Websites.
Search the Archives
Access over the years of investigative journalism and breaking reports
You May Have Missed
